SMS Pharmaceuticals Ltd
NSE:SMSPHARMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SMS Pharmaceuticals Ltd
Operating Income
SMS Pharmaceuticals Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SMS Pharmaceuticals Ltd
NSE:SMSPHARMA
|
Operating Income
₹1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Operating Income
₹63.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Operating Income
₹53.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Operating Income
₹135.6B
|
CAGR 3-Years
42%
|
CAGR 5-Years
18%
|
CAGR 10-Years
10%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Operating Income
₹59.6B
|
CAGR 3-Years
147%
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Operating Income
₹33.6B
|
CAGR 3-Years
19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
|
SMS Pharmaceuticals Ltd
Glance View
SMS Pharmaceuticals Ltd. is a holding company, which engages in the research, development and marketing of active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2007-02-25. The firm is engaged in the business of manufacturing active pharma ingredients (API) and their intermediates. The firm's API products include Ranitidine HCL (Form-2) USP / Ph.Eur, Famotidine USP / Ph. Eur / JP, Pantoprazole Sodium Sesquihydrate US/Ph. Eur, Itraconazole USP / Ph.Eur / JP, Lanoconazole USP / JP, Sumatriptan Succinate USP / Ph.Eur/ BP, Sumatriptan Base USP / Ph.Eur/ BP, Almotriptan Malate, Zolmitriptan, Rizatriptan Benzoate USP/ Ph.Eur, Eletriptan Hydrobromide Monohydrate, Sildenafil Citrate USP / Ph.Eur, Tadalafil USP / Ph.Eur, Vardenafil and others. The firm's manufacturing facilities are located in Bachupally, Hyderabad in the state of Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram district in Andhra Pradesh. Its research and development (R&D) center is located in Gagillapur, Hyderabad.
See Also
What is SMS Pharmaceuticals Ltd's Operating Income?
Operating Income
1.3B
INR
Based on the financial report for Dec 31, 2025, SMS Pharmaceuticals Ltd's Operating Income amounts to 1.3B INR.
What is SMS Pharmaceuticals Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
13%
Over the last year, the Operating Income growth was 36%.
